Eczema Across India: GAN Phase I Data From 127,309 People

November 10, 2026

Evidence review updated November 2026. This article explains population research; it is not a diagnosis or treatment plan.

A multicenter Global Asthma Network study of 20,084 younger children, 25,887 adolescents and 81,296 adults across India. [1] This matters because “eczema prevalence” can mean current symptoms, a clinician diagnosis, a billing code, a lifetime history or a modeled estimate. Those definitions answer different questions and should not be blended into one number. [2]

What the study measured

The target population was children, adolescents and parents across multiple Indian centers. Investigators used the study’s own sampling frame, case definition and severity measures. The resulting estimate describes that frame—not every person in the country and not an individual child or adult. International work repeatedly shows that estimates shift when symptom questionnaires are compared with physician diagnosis or medical records. [3] [4]

The main result

Eczema prevalence was 2.5% in children aged 6–7, 3.5% in adolescents and 9.9% in adults. Child estimates showed a modest decline compared with earlier ISAAC data. [1] The useful reading is comparative and bounded: the estimate tells us how common eczema appeared under the study’s rules. It does not show that a country, ethnicity, family choice or household exposure caused eczema. [5]

Why prevalence numbers can disagree

Case definition: A one-year symptom questionnaire will usually capture a different group than an insurance-code algorithm. Age structure: Eczema is often more common in childhood, so a younger sample can produce a higher estimate. Access to care: Claims and electronic records miss people who do not seek care. Recall: Lifetime-history questions can be forgotten or interpreted differently. Modeling: global estimates fill data gaps, but the uncertainty is real. [6] [7]

These are not technical footnotes. They determine whether two percentages can be compared at all. A careful reader should look for the denominator, age band, calendar years, diagnostic rule and whether uncertainty intervals were reported. [8]

What the result does—and does not—mean

The study supports planning for clinician access, caregiver education, sleep and mental-health support, and equitable availability of evidence-based care. It does not prove that a demographic characteristic is biologically causal. Differences may reflect environment, structural inequities, healthcare access, recognition on different skin tones, survey participation or diagnostic practice. [9] [10]

Participating centers do not constitute complete national surveillance, and adult respondents were parents or guardians. Questionnaire estimates depend on language and recall. This limitation statement is essential: association is not causation, and an estimated population rate is not an individual forecast.

Practical safety for babies and children

Infant rashes have many causes. Caregivers should seek prompt medical assessment for fever, poor feeding, rapidly spreading redness, pain, pus, honey-colored crusting, grouped blisters, eye involvement or a child who appears unwell. Do not start elimination diets, supplements, bleach baths, prescription steroids, calcineurin inhibitors, antibiotics or systemic medicines solely because of a prevalence study. Treatment choice and potency must match age, body site, severity and diagnosis. [11]

Where daily moisturizer care fits

Population epidemiology does not test a specific cosmetic moisturizer. Consistent fragrance-free moisturizing may be part of a clinician-guided routine for dry, sensitive or eczema-prone skin, but it does not replace diagnosis or prescription care. Dr. Arsy #003 was not the study product, was not evaluated in this research, and no study result here should be transferred to it.

For readers who want product information, the actual live 4-oz product is Dr. Arsy Moisturizer #003. It is presented here as a daily moisturizer for dry, sensitive and eczema-prone skin—not as a treatment, cure or prevention for eczema.

Questions to bring to a clinician

Does the diagnosis fit the rash pattern and age?
Could infection, contact allergy or another condition be involved?
Which moisturizer and prescription plan are appropriate for the body site?
What warning signs should trigger urgent care?
How should progress be measured at home?

Related evidence reviews

Bottom line

Eczema Across India: GAN Phase I Data From 127,309 People is best understood as a study of how eczema was identified and counted in a defined population. Its value is in the design, denominator and uncertainty—not in turning one percentage into a universal claim. [12]

References

← Back to Doctor's Notes